Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUBP 296
说明： Potent and selective kainate antagonist; selective for GluK1-containing receptors
化学名： (RS)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione
纯度： ≥98% (HPLC)
生物活性 for UBP 296
UBP 296 is a selective GluK1 (formally GluR5) subunit containing kainate receptor antagonist (apparent KD = 1.09 μM). Displays ~ 90-fold selectivity over AMPA receptors and recombinant hGluK2 (formally hGluR6) and GluK5 (formally KA2) containing kainate receptors. Has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers.
Active Enantiomer also available.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
技术数据 for UBP 296
| 分子量 | 333.3 |
| 公式 | C15H15N3O6 |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 745055-86-1 |
| PubChem ID | 11674376 |
| InChI Key | UUIYULWYHDSXHL-UHFFFAOYSA-N |
| Smiles | NC(CN1C=CC(=O)N(CC2=C(C=CC=C2)C(O)=O)C1=O)C(O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for UBP 296
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| 1eq. NaOH | 3.33 | 10 温和加热 | |
| DMSO | 3.33 | 10 |
制备储备液 for UBP 296
以下数据基于产品分子量 333.3。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 30 mL | 150.02 mL | 300.03 mL |
| 0.5 mM | 6 mL | 30 mL | 60.01 mL |
| 1 mM | 3 mL | 15 mL | 30 mL |
| 5 mM | 0.6 mL | 3 mL | 6 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for UBP 296
参考文献 for UBP 296
参考文献是支持产品生物活性的出版物。
More et al (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47 46 PMID: 15165833
Dolman et al (2005) Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J.Med.Chem. 48 7867 PMID: 16302825
If you know of a relevant reference for UBP 296, please let us know.
按产品操作查看相关产品
关键词: UBP 296, UBP 296 supplier, Selective, potent, kainate, antagonists, selective, GluR5-containing, receptors, Glutamate, Kainate, Receptors, iGluR, Ionotropic, UBP296, GluK1, 2078, Tocris Bioscience
1 篇 UBP 296 的引用文献
引用文献是使用了 Tocris 产品的出版物。 UBP 296 的部分引用包括：
Albiñana et al (2015) Chondroitin Sulfate Induces Depression of Synaptic Transmission and Modulation of Neuronal Plasticity in Rat Hippocampal Slices. Neural Plast 2015 463854 PMID: 26075099
您是否知道使用了 Tocris UBP 296 的优秀论文？ 请告知我们.
UBP 296 的评论
目前没有该产品的评论。 Be the first to review UBP 296 and earn rewards!
Have you used UBP 296?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.